(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Windows to the Previous: An Excursion Through the World's Notable Engineering - 2'Israel has the right to continue its attacks,' Lebanese Foreign Minister announces
- 3Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- 4Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- 5Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- We may be witnessing the messy death of a star in real time
- Joshua Made Last-Second Seat Change That Saved His Life
- What's going around right now? COVID, flu, stomach bug on the rise
- Europe picks companies to help build Argonaut moon lander
- Israel faces widespread condemnation as NGO ban comes into effect
- Vote in favor of the handheld vacuum that you love for its strong attractions!
- Vote In favor of Your Number one Sort Of Blossoms
- New dinosaur tracks in Italy illustrate herds moving in unison
